MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin

E. Cecchin, G. Perrone, S. Nobili, J. Polesel, E. De Mattia, C. Zanusso, P. Petreni, S. Lonardi, N. Pella, M. D'Andrea, D. Errante, F. Rizzolio, T. Mazzei, I. Landini, E. Mini, G. Toffoli

Research output: Contribution to journalArticlepeer-review

Abstract

Adjuvant treatment based on fluoropyrimidines (FL) improves the prognosis of stage II/III colorectal cancer (CRC). Validated predictive/prognostic biomarkers would spare therapy-related morbidity in patients with a good prognosis. We compared the impact of a set of 22 FL-related polymorphisms with the prognosis of two cohorts of CRC patients treated with adjuvant FL with or without OXA, including a total of 262 cases. 5,10-Methylentetrahydrofolate reductase (MTHFR) MTHFR-1298 A>C (rs1801131) polymorphism had a concordant effect: MTHFR-rs1801131-1298CC genotype carriers had a worse disease free survival (DFS) in both the cohorts. In the pooled population MTHFR-rs1801131-1298CC carriers had also a worse overall survival. We computed a clinical score related to DFS including MTHFR-rs1801131, tumor stage, sex and tumor location, where rs1801131 is the most detrimental factor (hazard ratio=5.3, 95% confidence interval=2.2-12.9; P-value=0.0006). MTHFR-rs1801131 is a prognostic factor that could be used as an additional criteria for the choice of the proper adjuvant regimen in stage II/III colorectal cancer patients.

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalPharmacogenomics Journal
Volume15
Issue number3
DOIs
Publication statusPublished - Jun 26 2015

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics
  • Medicine(all)

Fingerprint Dive into the research topics of 'MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin'. Together they form a unique fingerprint.

Cite this